A. women tend to present with more symptoms of HF B. survival rates are lower in women with HF C. women tend to develop HF at a younger age versus men D. all of the above

A. HF with reduced ejection fraction (HFrEF) B. HF with mid-range ejection fraction (HFmrEF) C. HF with preserved ejection fraction (HFpEF) D. No distinction has been noted between men and women regarding prevalence of HF subtypes

A. Increased diuretic dose is recommended for women over age 80 with HF B. Angiotensin receptor blocker (ARB) is preferred over angiotensin converting enzyme inhibitor (ACEi) in women with HF C. Angiotensin receptor/neprilysin inhibitor (ARNI) is more likely to be effective in women D. Guideline recommendations for medication therapy do not differ between men and women with HF

A. Consider replacing her ACEi with an ARB B. Consider replacing her ACEi with ARNI C. Consider adding ivabradine to the regimen D. Consider adding hydralazine/isosorbide dinitrate

A. Enalapril, 20 mg twice daily B. Carvedilol, 12.5 mg once daily C. Spironolactone, 25 mg once daily D. All doses are within target range for this patient

A. NYHA Class III, ACC/AHA Stage D B. NYHA Class II, ACC/AHA Stage A C. NYHA Class I, ACC/AHA Stage B D. NYHA Class IV, ACC/AHA Stage C

A. Diuretic for fluid overload B. Consider use of ACEi, ARB or MRA C. Consider use of beta blocker D. All of the above